{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:26:45Z","timestamp":1792567605521,"version":"4.5.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society of America","doi-asserted-by":"publisher","award":["R6508-18"],"award-info":[{"award-number":["R6508-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society of America","doi-asserted-by":"publisher","award":["1R01CA205607-01"],"award-info":[{"award-number":["1R01CA205607-01"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The relationship between the checkpoint kinase Chk1 and the STAT3 pathway was examined in multiple myeloma cells. Gene expression profiling of U266 cells exposed to low (nmol\/L) Chk1 inhibitor [PF-477736 (PF)] concentrations revealed STAT3 pathway-related gene downregulation (e.g., BCL-XL, MCL-1, c-Myc), findings confirmed by RT-PCR. This was associated with marked inhibition of STAT3 Tyr705 (but not Ser727) phosphorylation, dimerization, nuclear localization, DNA binding, STAT3 promoter activity by chromatin immunoprecipitation assay, and downregulation of STAT-3-dependent proteins. Similar findings were obtained in other multiple myeloma cells and with alternative Chk1 inhibitors (e.g., prexasertib, CEP3891). While PF did not reduce GP130 expression or modify SOCS or PRL-3 phosphorylation, the phosphatase inhibitor pervanadate antagonized PF-mediated Tyr705 dephosphorylation. Significantly, PF attenuated Chk1-mediated STAT3 phosphorylation in in vitro assays. Surface plasmon resonance analysis suggested Chk1\/STAT3 interactions and PF reduced Chk1\/STAT3 co-immunoprecipitation. Chk1 CRISPR knockout or short hairpin RNA knockdown cells also displayed STAT3 inactivation and STAT3-dependent protein downregulation. Constitutively active STAT3 diminished PF-mediated STAT3 inactivation and downregulate STAT3-dependent proteins while significantly reducing PF-induced DNA damage (\u03b3H2A.X formation) and apoptosis. Exposure of cells with low basal phospho-STAT3 expression to IL6 or human stromal cell conditioned medium activated STAT3, an event attenuated by Chk1 inhibitors. PF also inactivated STAT3 in primary human CD138+ multiple myeloma cells and tumors extracted from an NSG multiple myeloma xenograft model while inhibiting tumor growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications:<\/jats:title>\n                    <jats:p>These findings identify a heretofore unrecognized link between the Chk1 and STAT3 pathways and suggest that Chk1 pathway inhibitors warrant attention as novel and potent candidate STAT3 antagonists in myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1541-7786.mcr-21-0366","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:15:44Z","timestamp":1636974944000},"page":"456-467","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells"],"prefix":"10.1158","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5457-7532","authenticated-orcid":false,"given":"Liang","family":"Zhou","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Pei","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."},{"name":"2Division of Molecular Diagnostics, Department of Pathology, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Ning","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Hu","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-5930","authenticated-orcid":false,"given":"Sri Lakshmi","family":"Chalasani","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Sharma","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewel","family":"Nkwocha","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9664","authenticated-orcid":false,"given":"Jonathan","family":"Yu","sequence":"additional","affiliation":[{"name":"3Biology Department, University of Virginia, Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"4Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia."},{"name":"5Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said M.","family":"Sebti","sequence":"additional","affiliation":[{"name":"4Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia."},{"name":"6Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9320","authenticated-orcid":false,"given":"Steven","family":"Grant","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia."},{"name":"4Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"2025112608240010600_bib1","first-page":"136","article-title":"Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2025112608240010600_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers"},{"key":"2025112608240010600_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5045\/br.2017.52.4.293","article-title":"STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma","volume":"52","author":"Jung","year":"2017","journal-title":"Blood Res"},{"key":"2025112608240010600_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112608240010600_bib5","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/onc.2010.63","article-title":"Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1\/2, and ERK1\/2)","volume":"29","author":"Aziz","year":"2010","journal-title":"Oncogene"},{"key":"2025112608240010600_bib6","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1128\/MCB.17.11.6508","article-title":"STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation","volume":"17","author":"Chung","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2025112608240010600_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2025112608240010600_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","article-title":"Feedback activation of STAT3 as a cancer drug-resistance mechanism","volume":"37","author":"Zhao","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"2025112608240010600_bib9","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2002-01-0102","article-title":"In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6\/gp130\/STAT3 pathway","volume":"100","author":"Chatterjee","year":"2002","journal-title":"Blood"},{"key":"2025112608240010600_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/leu.2010.289","article-title":"The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival","volume":"25","author":"Scuto","year":"2011","journal-title":"Leukemia"},{"key":"2025112608240010600_bib11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"2025112608240010600_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"2025112608240010600_bib13","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/0008-5472.CAN-12-3175","article-title":"A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res"},{"key":"2025112608240010600_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int J Cancer"},{"key":"2025112608240010600_bib15","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","article-title":"Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25","volume":"277","author":"Sanchez","year":"1997","journal-title":"Science"},{"key":"2025112608240010600_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4161\/cc.9.6.11155","article-title":"Targeting Chk1 in the replicative stress response","volume":"9","author":"Dai","year":"2010","journal-title":"Cell Cycle"},{"key":"2025112608240010600_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025112608240010600_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-16-0352","article-title":"Combining Chk1\/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma","volume":"16","author":"Zeng","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2025112608240010600_bib19","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-11-0949","article-title":"The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells","volume":"11","author":"Landau","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2025112608240010600_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2025112608240010600_bib21","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025112608240010600_bib22","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/onc.2010.343","article-title":"Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents","volume":"29","author":"Zenvirt","year":"2010","journal-title":"Oncogene"},{"key":"2025112608240010600_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.2013020161","article-title":"A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury","volume":"25","author":"Ajay","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025112608240010600_bib24","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","article-title":"A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"2025112608240010600_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1292\/jvms1939.49.575","article-title":"Bovine erythrocyte fractionation in Percoll density gradients","volume":"49","author":"Asano","year":"1987","journal-title":"Nihon Juigaku Zasshi"},{"key":"2025112608240010600_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2014.10.009","article-title":"Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR\/ABL(+) leukemia cells","volume":"39","author":"Nguyen","year":"2015","journal-title":"Leuk Res"},{"key":"2025112608240010600_bib27","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1158\/0008-5472.CAN-04-2434","article-title":"Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation","volume":"64","author":"Syljuasen","year":"2004","journal-title":"Cancer Res"},{"key":"2025112608240010600_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11010-015-2424-0","article-title":"Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro","volume":"406","author":"Li","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"2025112608240010600_bib29","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","article-title":"IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma","volume":"79","author":"Chong","year":"2019","journal-title":"Cancer Res"},{"key":"2025112608240010600_bib30","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J Biol Chem"},{"key":"2025112608240010600_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"2025112608240010600_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1478-811X-11-83","article-title":"Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain","volume":"11","author":"Mohr","year":"2013","journal-title":"Cell Commun Signal"},{"key":"2025112608240010600_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2025112608240010600_bib34","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1038\/ncomms14290","article-title":"THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors","volume":"8","author":"Cayrol","year":"2017","journal-title":"Nat Commun"},{"key":"2025112608240010600_bib35","doi-asserted-by":"crossref","first-page":"15711","DOI":"10.1038\/s41598-020-72594-3","article-title":"Helicobacter pylori infection induces STAT3 phosphorylation on Ser727 and autophagy in human gastric epithelial cells and mouse stomach","volume":"10","author":"Piao","year":"2020","journal-title":"Sci Rep"},{"key":"2025112608240010600_bib36","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/sj.onc.1203481","article-title":"Serine phosphorylation of STATs","volume":"19","author":"Decker","year":"2000","journal-title":"Oncogene"},{"key":"2025112608240010600_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cell.2007.01.021","article-title":"Chemical genetics: where genetics and pharmacology meet","volume":"128","author":"Knight","year":"2007","journal-title":"Cell"},{"key":"2025112608240010600_bib38","doi-asserted-by":"crossref","first-page":"35812","DOI":"10.1074\/jbc.M605288200","article-title":"Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase","volume":"281","author":"Liu","year":"2006","journal-title":"J Biol Chem"},{"key":"2025112608240010600_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"2025112608240010600_bib40","doi-asserted-by":"crossref","first-page":"11289","DOI":"10.1073\/pnas.191557598","article-title":"Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast","volume":"98","author":"Lopez-Girona","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112608240010600_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cancers10060206","article-title":"Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional, reconstructed bone marrow model","volume":"10","author":"Huang","year":"2018","journal-title":"Cancers"},{"key":"2025112608240010600_bib42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discov"},{"key":"2025112608240010600_bib43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2613.2010.00734.x","article-title":"STAT3 modulates the DNA damage response pathway","volume":"91","author":"Barry","year":"2010","journal-title":"Int J Exp Pathol"},{"key":"2025112608240010600_bib44","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int J Cancer"},{"key":"2025112608240010600_bib45","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers11091320","article-title":"Everything in moderation: lessons learned by exploiting moderate replication stress in cancer","volume":"11","author":"Nazareth","year":"2019","journal-title":"Cancers"},{"key":"2025112608240010600_bib46","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-18-0972","article-title":"Inhibition of the replication stress response is a synthetic vulnerability in SCLC that acts synergistically in combination with cisplatin","volume":"18","author":"Nagel","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2025112608240010600_bib47","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2007-04-083204","article-title":"MEK1\/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism","volume":"110","author":"Pei","year":"2007","journal-title":"Blood"},{"key":"2025112608240010600_bib48","doi-asserted-by":"crossref","first-page":"11528","DOI":"10.1074\/jbc.M413930200","article-title":"Activation of Stat3 sequence-specific DNA binding and transcription by p300\/CREB-binding protein-mediated acetylation","volume":"280","author":"Wang","year":"2005","journal-title":"J Biol Chem"},{"key":"2025112608240010600_bib49","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.105.561522","article-title":"Role of the protein kinase C-epsilon-Raf-1-MEK-1\/2-p44\/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning","volume":"112","author":"Xuan","year":"2005","journal-title":"Circulation"}],"container-title":["Molecular Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mcr\/article-pdf\/20\/3\/456\/3051107\/456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mcr\/article-pdf\/20\/3\/456\/3051107\/456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:24:17Z","timestamp":1764163457000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mcr\/article\/20\/3\/456\/681666\/Chk1-Inhibition-Potently-Blocks-STAT3-Tyrosine705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,3]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1541-7786.mcr-21-0366","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1541-7786.22527477","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527465","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527483","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527471","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527468.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527459","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527468","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527459.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527456","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527456.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527465.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527462","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527462.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527486","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527474","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527480","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527471.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527474.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527477.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527489.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527486.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527483.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.22527480.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1541-7786.c.6545436","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1541-7786.c.6545436.v1","asserted-by":"object"}]},"ISSN":["1541-7786","1557-3125"],"issn-type":[{"value":"1541-7786","type":"print"},{"value":"1557-3125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}